ClinicalTrials.gg
CompletedNCT03232073OPTIMUM-LTUpdated Jun 22, 2025Results posted

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

A Phase 3 interventional study of Ponesimod in Multiple Sclerosis, sponsored by Actelion. Completed at 148 sites in 28 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-22.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
877
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 86 studies in Multiple Sclerosis with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Multiple Sclerosis · Russian Federation.

Enrollment
21st of 83
877 · median 402
Started
2017
with 2 others
Phase 3
40 of 86
none open now
Registered
73rd of 86
by date
Lead sponsor
5 of 86
Actelion

Among the 86 studies in Multiple Sclerosis with a site in Russian Federation, this one is the 21st largest by enrollment of the 83 interventional ones that give a count, is one of 3 that started in 2017, is one of 40 in phase 3, and was the 73rd registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 86 studies in Multiple Sclerosis with a site in Russian Federation is open now. The open studies under Multiple Sclerosis, anywhere →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 86 studies in Multiple Sclerosis with a site in Russian Federation as a file.
02

Study summary

The study AC-058B301 (OPTIMUM; NCT02425644) has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with relapsing multiple sclerosis (RMS). The AC-058B303 study is the long-term extension for the core study AC-058B301. The purpose of this long term extension of the core study AC-058B301 is to characterize the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with RMS.

Read the detailed description

The AC-058B303 study (extension study) is the long-term extension for the AC-058B301 study (core study). The core study has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with RMS. The subjects are treated with either ponesimod or the active comparator, teriflunomide in the core study. The purpose of this long term extension of the core study is to characterize the long-term safety and control of disease of ponesimod in subjects with RMS. In particular, the study will allow to observe potential adverse events which may only occur after long term treatment with ponesimod. The study will also investigate the effect of re-initiation of ponesimod after a brief interruption in a relatively large population (all subjects treated with ponesimod in the core study and eligible for the extension study) on disease activity in terms of relapses and MS-related MRI lesions. There is currently limited guidance on when a new MS treatment should be started after discontinuation of teriflunomide and the study will contribute with data on safety and efficacy of switching from teriflunomide to ponesimod after an interruption as mandated by the protocol. The study will also allow confirmation of sustained efficacy of ponesimod in terms of relapses, MRI lesions and reduction of disability accumulation during long-term treatment. In addition, combined data from the core study together with the results of the current extension study will allow comparison of MS activity in subjects who were switched from teriflunomide to ponesimod versus those who were treated with ponesimod in both studies.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Subjects with MS having completed the double-blind treatment in the core study as scheduled
  3. Compliance with teriflunomide elimination procedure
  4. Women of (WOCBP) must have a negative pre-treatment urine pregnancy test, must agree to undertake 4-weekly urine pregnancy tests, and must have been using reliable methods of . Fertile male subjects participating in the study must agree to use a condom.

Exclusion criteria

Exclusion Criteria:

  1. Any of the following cardiovascular conditions on Day 1 pre-dose:

    1. Resting heart rate (HR) \< 50 bpm;
    2. Presence of second degree atrioventricular (AV) block or third degree AV block or a interval > 470 ms (females), > 450 ms (males);
  2. Any of the following alerts from central laboratory at Visit 14 of the core study (EOT) which was confirmed as an alert at repeated testing or not repeated prior to FU1 of the core study:

    1. Lymphocyte count: \< 0.2 x 109/L;
    2. \<1.0 × 109/L;
    3. count \< 50 × 109/L;
    4. \< 30 mL/min
  3. At Visit 14 of the core study (EOT) >30% decrease from core study baseline and/or FVC;
  4. , persistent respiratory AEs (e.g., dyspnea) not resolved prior to first dosing in the extension study.
  5. Macular edema at any time between Visit 1 (Screening) in the core study and Day 1 of the extension study.
  6. Presence of the following at core study Visit 14 (EOT, Week 108), FU1, or abbreviated visit FU2, or on Day 1 of the extension study pre-dose:

    1. Suspected opportunistic infection of the CNS or any other infection which, in the opinion of the investigator, contraindicates re-start of the study drug;
    2. Stevens-Johnson syndrome or toxic epidermal necrolysis or drug reaction with eosinophilia and systemic symptoms.
  7. Need for and intention to administer forbidden study treatment-concomitant therapy
  8. Women who are pregnant or lactating.
  9. Male subjects wishing to parent a child;
  10. Treatment with any MS Disease Modifying Therapies;
  11. Any other clinically relevant medical or surgical condition, which, in the opinion of the investigator, would put the subject at risk by participating in the study;
  12. Subjects unlikely to comply with the extension study protocol based on investigator best judgment
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
877 participants (actual)

Study arms

  • Experimental
    Ponesimod

    20 mg administered orally once daily

    Drug: Ponesimod

Interventions

  • Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15

06

What researchers measure

Primary outcomes

  1. Annualized Confirmed Relapse Rate (ARR)

    ARR: number of confirmed relapses per patient-year. Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours, in the absence of fever or infection. A confirmed relapse is identified when a patient's symptoms worsen as indicated by an increase in their Expanded Disability Status Scale (EDSS) or Functional Systems (FS) scores, consistent with previous clinically stable assessments. Specific criteria for a confirmed relapse include: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0 (normal)-10 (death due to MS).

    Time frame: From randomization in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months

  2. Time From Core Study Randomization to First Confirmed Relapse

    Time to first confirmed relapse: date of first confirmed relapse (in either core or extension study) minus date of randomization in core study+1 day. Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours in absence of fever or infection. A confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Specific criteria for confirmed relapse are: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0(normal)-10(death due to MS).

    Time frame: From randomization in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months

  3. Time to First 12-week Confirmed Disability Accumulation (CDA)

    Time to first 12-week CDA is defined as start date of the first 12-week CDA minus date of randomization in the core study + 1 day. A 12-week CDA is defined as a 12-week sustained increase from the core baseline EDSS score, which is confirmed at a scheduled visit after 12-weeks. CDA is defined as: (a) Sustained increase of at least 1.5 in EDSS for participants with a core baseline EDSS score of 0; (b) Sustained increase of at least 1.0 in EDSS for participants with a core baseline EDSS score of 1.0 to 5.0; (c) Sustained increase of at least 0.5 in EDSS for participants with a core baseline EDSS score \>=5.5, confirmed after 12 weeks. EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.

    Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months

  4. Time to First 24-week Confirmed Disability Accumulation (CDA)

    Time to first 24-week CDA was defined as start date of the first 24-week CDA minus date of randomization in the core study + 1 day. A 24-week CDA was defined as a 24-week sustained increase from the core baseline EDSS score, which is confirmed at a scheduled visit after 24-weeks. CDA was defined as: (a) Sustained increase of at least 1.5 in EDSS for participants with a core baseline EDSS score of 0; (b) Sustained increase of at least 1.0 in EDSS for participants with a core baseline EDSS score of 1.0 to 5.0; (c) Sustained increase of at least 0.5 in EDSS for participants with a core baseline EDSS score \>=5.5, confirmed after 24 weeks. EDSS was an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.

    Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months

  5. Percentage of Participants With Absence of Relapses

    Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours in absence of fever or infection. A confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Specific criteria for confirmed relapse: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0(normal)-10(death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.

    Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months

  6. Change From Baseline in Expanded Disability Status Scale (EDSS)

    EDSS is ordinal clinical rating scale based on standard neurological examination for assessing neurological disability and impairment in MS. Seven FS scores were rated on a scale ranged from 0 to 5 or 6 to assess visual, brain, stem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral functions while ambulation was scored on scale ranged from 0 to 12 to assess walking distance and assistance. Individual FS scores were then used in conjugation with ambulation score to obtain EDSS score which ranged from 0 (normal) to 10 (death due to MS) in 0.5 unit increments that represented higher levels of disability. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.

    Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months

  7. Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Three Components (NEDA-3) at Extension End of Study

    NEDA-3 up to extension EOS is defined by the absence of confirmed relapse, gadolinium-enhancing (Gd+ T1) lesions, new or enlarging T2 lesions, and 12-week CDA. If at least one of the criteria was not fulfilled or the participant discontinued treatment prematurely, the participant was not considered to have achieved NEDA-3. Confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging: 0 (normal)-10 (death due to MS). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.

    Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months

  8. Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Four Components (NEDA-4) at Extension End of Study

    NEDA-4 up to EOS is defined by the absence of confirmed relapse, Gd+ T1 lesions, new or enlarging T2 lesions, 12-week CDA until EOS, and absence of annual brain volume decrease \>=0.4% from core baseline up to extension EOS. If at least one of the criteria was not fulfilled or the participant discontinued treatment prematurely, the participant was not considered to have achieved NEDA-4. Confirmed relapse: when patient's symptoms worsen by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging: 0 (normal)-10 (death due to MS). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in core study for each outcome measure and each participant individually.

    Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months

  9. Percent Change From Baseline in Brain Volume (PCBV) Measured by Magnetic Resonance Imaging (MRI)

    Percent change from baseline in brain volume (PCBV) measured by MRI were reported. Normalized Brain Volume at core baseline was measured in cubic centimeter (cm\^3). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.

    Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months

  10. Cumulative Number of Combined Unique Active Lesions (CUAL) Measured by MRI

    CUALs was calculated as sum of new T1 Gadolinium-enhanced (Gd+) lesions and new or enlarging T2 lesions (without double-counting of lesions) from baseline up to extension EOS based on the Magnetic resonance imaging (MRI). Average number of lesions per patient-year were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.

    Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months

  11. Number of Gadolinium-enhancing (Gd+) T1 Lesions Measured by MRI

    Number of Gd+ T1 lesions measured by MRI were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. For this outcome measure, results presented here are for the Extension end-of-treatment visit.

    Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months

  12. Cumulative Number of New or Enlarging T2 Lesions Measured by MRI

    Cumulative number of new or enlarging T2 lesions measured by MRI were reported. Average number of lesions per year were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.

    Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months

  13. Change From Baseline in Volume of MRI Lesions (T2 Lesions and T1 Hypointense Lesions)

    Change from baseline in volume of MRI lesions (T2 lesions, T1 hypointense lesions) were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.

    Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months

  14. Number of Participants With Absence of MRI Lesions (Gd+ T1 Lesions, New or Enlarging T2 Lesions)

    Number of participants with absence of MRI lesions (Gd+ T1 lesions, new or enlarging T2 lesions) were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.

    Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months

  15. Percentage of Gd+ Lesions at Baseline Evolving to Persistent Black Holes (PBHs)

    Percentage of Gd+ lesions at baseline evolving to PBHs were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.

    Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months

  16. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs were reported. An AE is any untoward medical event that occurs in a participants being administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs occurring from start of treatment up to treatment end date + 15 days.

    Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days

  17. Number of Participants With Treatment-emergent New Morphological Electrocardiogram (ECG) Abnormalities

    Number of participants with treatment-emergent new morphological ECG abnormalities were reported. Treatment-emergent new morphological ECG abnormalities are defined as those ECG abnormalities occurring from start of treatment up to treatment end date + 15 days.

    Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days

  18. Actual Values of 12-lead ECG Measurements up to End of Study Treatment: Heart Rate

    Actual values of 12-lead ECG measurements up to end of study treatment: heart rate were reported. In this outcome measure, results were presented for extension end of treatment visit.

    Time frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months

  19. Actual Values of 12-lead ECG Measurements up to End of Study Treatment: PR, QRS, QT, QTcB, QTcF

    Actual values of 12-lead ECG measurements up to end of study treatment: PR, QRS, QT, QTcB, QTcF were reported. In this outcome measure, results were presented for extension end of treatment visit.

    Time frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months

  20. Change in Heart Rate (HR) From Baseline up to End of Study Treatment

    Change in heart rate (HR) from baseline up to end of study treatment were reported.

    Time frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months

  21. Change in PR, QRS, QT, QTcB, QTcF From Baseline up to End of Study Treatment

    Change in PR, QRS, QT, QTcB, QTcF from baseline up to end of study treatment were reported.

    Time frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months

  22. Absolute Values in Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) Values

    Absolute values in FEV1 and FVC values were reported. FEV1: the maximal volume of air exhaled from the lungs in 1 second of a forced expiration from a position of full inspiration as measured by spirometer. FVC: the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. Results are presented for extension end of treatment visit.

    Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months

  23. Percent Change in (FEV1) and Forced Vital Capacity (FVC) From Baseline (%)

    Percent change in FEV1 and FVC from baseline (%) were reported. FEV1: the maximal volume of air exhaled from the lungs in 1 second of a forced expiration from a position of full inspiration as measured by spirometer. FVC: the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. In this outcome measure, results were presented for extension end of treatment visit.

    Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months

  24. Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)

    Number of participants with treatment-emergent SAEs were reported. A SAE was defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or was an important medical event. Treatment-emergent SAEs are defined as SAEs occurring from start of treatment up to treatment end date + 15 days.

    Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days

  25. Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)

    Number of participants with treatment-emergent AESIs were reported. AESIs included bradyarrhythmia occurred post-first dose, macular edema, bronchoconstriction, severe liver injury, serious opportunistic infections including progressive multifocal leukoencephalopathy (PML), skin cancer, non-skin malignancy, convulsions, unexpected neurological or psychiatric symptoms/signs (posterior reversible encephalopathy syndrome \[PRES\], acute disseminated encephalomyelitis \[ADEM\], and atypical MS relapses). Treatment-emergent AESIs are defined as AESIs occurring from start of treatment up to treatment end date + 15 days.

    Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days

  26. Number of Participants With AE Leading to Premature Discontinuation of Study Treatment

    Number of participants with AE leading to premature discontinuation of study treatment were reported. An AE is any untoward medical event that occurs in a participant being administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs occurring from start of treatment up to treatment end date + 15 days.

    Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days

  27. Number of Participants With Treatment-emergent Decrease From Baseline >20% and >30% in FEV1 or FVC

    Number of participants with treatment-emergent decrease from baseline \>20% and \>30% in FEV1 or FVC were reported. Treatment-emergent is defined as events occurring from start of treatment up to treatment end date + 15 days (that is, findings not present at any assessment prior to first treatment in the extension study).

    Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days

  28. Number of Participants With Treatment-emergent Decrease of >20% Points in Percent Predicted FEV1 and FVC From Baseline

    Number of participants with treatment-emergent decrease of \>20% points in percent predicted FEV1 and FVC from baseline were reported. Treatment-emergent is defined as events occurring from start of treatment up to treatment end date + 15 days (that is, findings not present at any assessment prior to first treatment in the extension study).

    Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days

  29. Number of Participants With a Decrease of >=200 mL or >=12% in FEV1 or FVC From Baseline to EOT

    Number of participants with a decrease of \>=200 mL or \>=12% in FEV1 or FVC from baseline to EOT were planned to be reported. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. This endpoint is not relevant as a substantial proportion of patients continued onto post-treatment disease-modifying therapy (DMT), hence it cannot provide an assessment of reversibility.

    Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months

  30. Change in FEV1 and FVC (% Predicted) From Baseline to End of Treatment (EOT)

    Change in FEV1 and FVC (% predicted) from baseline to EOT were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.

    Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months

  31. Change in FEV1 and FVC (% Predicted) From Baseline to End of Study (EOS)

    Change in FEV1 and FVC (% predicted) from baseline to EOS were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.

    Time frame: From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months

  32. Absolute Change in Lung Diffusion Capacity as Assessed by Diffusing Capacity for the Lungs Measured Using Carbon Monoxide (DL[CO]) From Baseline

    Absolute change in lung diffusion capacity as assessed by DL\[CO\] from baseline were reported. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.

    Time frame: From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months

  33. Change in DL[CO] (% Predicted) From Baseline to EOT

    Change in DL\[CO\] (% predicted) from baseline to EOT were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.

    Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months

  34. Change in DL[CO] (% Predicted) From Baseline to EOS

    Change in DL\[CO\] (% predicted) from baseline to EOS were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.

    Time frame: From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months

Other outcomes

  1. Actual Values of 12-lead ECG Measurements on Day of First Re-initiation (Day 1) of Study Drug: Heart Rate

    Actual values of 12-lead ECG measurements on day of first Re-initiation (Day 1) of study drug: heart rate were reported.

    Time frame: Extension analysis period: Predose, 1, 2, 3, 4 hours post dose on Day 1 of re-initiation (re-initiation could occur on any day during the treatment period when drug was interrupted for at least 3 consecutive days [up to 71.8 months])

  2. Actual Values of 12-lead ECG Measurements on Day of First Re-initiation (Day 1) of Study Drug: PR, QRS, QT, QTcB, QTcF

    Actual values of 12-lead ECG measurements on day of first Re-initiation (Day 1) of study drug: PR, QRS, QT, QTcB, QTcF were reported.

    Time frame: Extension analysis period: Predose, 1, 2, 3, 4 hours post dose on Day 1 of re-initiation (re-initiation could occur on any day during the treatment period when drug was interrupted for at least 3 consecutive days [up to 71.8 months])

07

Results

Posted Feb 21, 2025
Limitations and caveats
Due to limited availability of COVID-19 vaccine-naïve MS patients, the COVID-19 vaccination sub-study was cancelled and removed from the protocol after implementation of amendment 5.

Participant flow

Total of 877 participants entered this extension study from the core study (NCT02425644) and all received at least one dose of ponesimod 20 milligrams (mg) treatment.

Participant flow — Overall Study
MilestonePonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Started439438
Completed352371
Not completed8767
Withdrew: Death10
Withdrew: Adverse event712
Withdrew: Lost to follow-up66
Withdrew: Lack of efficacy108
Withdrew: Physician decision92
Withdrew: Withdrawal by subject5439

Outcome measures

PrimaryAnnualized Confirmed Relapse Rate (ARR)

ARR: number of confirmed relapses per patient-year. Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours, in the absence of fever or infection. A confirmed relapse is identified when a patient's symptoms worsen as indicated by an increase in their Expanded Disability Status Scale (EDSS) or Functional Systems (FS) scores, consistent with previous clinically stable assessments. Specific criteria for a confirmed relapse include: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0 (normal)-10 (death due to MS).

Time frame:
From randomization in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Reported as:
Mean · relapses per patient-year
Annualized Confirmed Relapse Rate (ARR)
relapses per patient-yearPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Annualized Confirmed Relapse Rate (ARR)0.143 (0.123 to 0.167)0.184 (0.158 to 0.213)
Statistical analysis
  • Ponesimod 20 mg (Core and Extension Study) vs Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) · Treatment effect (rate ratio): 0.779 · 95% CI 0.629 to 0.965
PrimaryTime From Core Study Randomization to First Confirmed Relapse

Time to first confirmed relapse: date of first confirmed relapse (in either core or extension study) minus date of randomization in core study+1 day. Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours in absence of fever or infection. A confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Specific criteria for confirmed relapse are: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0(normal)-10(death due to MS).

Time frame:
From randomization in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Reported as:
Median · Weeks
Time From Core Study Randomization to First Confirmed Relapse
WeeksPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Time From Core Study Randomization to First Confirmed Relapse402.71 (82.29 to NA)NA (53.57 to NA)
PrimaryTime to First 12-week Confirmed Disability Accumulation (CDA)

Time to first 12-week CDA is defined as start date of the first 12-week CDA minus date of randomization in the core study + 1 day. A 12-week CDA is defined as a 12-week sustained increase from the core baseline EDSS score, which is confirmed at a scheduled visit after 12-weeks. CDA is defined as: (a) Sustained increase of at least 1.5 in EDSS for participants with a core baseline EDSS score of 0; (b) Sustained increase of at least 1.0 in EDSS for participants with a core baseline EDSS score of 1.0 to 5.0; (c) Sustained increase of at least 0.5 in EDSS for participants with a core baseline EDSS score \>=5.5, confirmed after 12 weeks. EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.

Time frame:
From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Reported as:
Median · Weeks
Time to First 12-week Confirmed Disability Accumulation (CDA)
WeeksPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Time to First 12-week Confirmed Disability Accumulation (CDA)NA (NA to NA)NA (254.86 to NA)
PrimaryTime to First 24-week Confirmed Disability Accumulation (CDA)

Time to first 24-week CDA was defined as start date of the first 24-week CDA minus date of randomization in the core study + 1 day. A 24-week CDA was defined as a 24-week sustained increase from the core baseline EDSS score, which is confirmed at a scheduled visit after 24-weeks. CDA was defined as: (a) Sustained increase of at least 1.5 in EDSS for participants with a core baseline EDSS score of 0; (b) Sustained increase of at least 1.0 in EDSS for participants with a core baseline EDSS score of 1.0 to 5.0; (c) Sustained increase of at least 0.5 in EDSS for participants with a core baseline EDSS score \>=5.5, confirmed after 24 weeks. EDSS was an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.

Time frame:
From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Reported as:
Median · Weeks
Time to First 24-week Confirmed Disability Accumulation (CDA)
WeeksPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Time to First 24-week Confirmed Disability Accumulation (CDA)NA (NA to NA)NA (313.29 to NA)
PrimaryPercentage of Participants With Absence of Relapses

Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours in absence of fever or infection. A confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Specific criteria for confirmed relapse: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0(normal)-10(death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.

Time frame:
From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Absence of Relapses
Percentage of ParticipantsPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Percentage of Participants With Absence of Relapses56.751.6
PrimaryChange From Baseline in Expanded Disability Status Scale (EDSS)

EDSS is ordinal clinical rating scale based on standard neurological examination for assessing neurological disability and impairment in MS. Seven FS scores were rated on a scale ranged from 0 to 5 or 6 to assess visual, brain, stem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral functions while ambulation was scored on scale ranged from 0 to 12 to assess walking distance and assistance. Individual FS scores were then used in conjugation with ambulation score to obtain EDSS score which ranged from 0 (normal) to 10 (death due to MS) in 0.5 unit increments that represented higher levels of disability. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.

Time frame:
From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Reported as:
Mean · Score on a scale
Change From Baseline in Expanded Disability Status Scale (EDSS)
Score on a scalePonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Change From Baseline in Expanded Disability Status Scale (EDSS)0.16 ± 1.0080.34 ± 1.105
PrimaryPercentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Three Components (NEDA-3) at Extension End of Study

NEDA-3 up to extension EOS is defined by the absence of confirmed relapse, gadolinium-enhancing (Gd+ T1) lesions, new or enlarging T2 lesions, and 12-week CDA. If at least one of the criteria was not fulfilled or the participant discontinued treatment prematurely, the participant was not considered to have achieved NEDA-3. Confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging: 0 (normal)-10 (death due to MS). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.

Time frame:
From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Three Components (NEDA-3) at Extension End of Study
Percentage of ParticipantsPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Three Components (NEDA-3) at Extension End of Study17.57.5
PrimaryPercentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Four Components (NEDA-4) at Extension End of Study

NEDA-4 up to EOS is defined by the absence of confirmed relapse, Gd+ T1 lesions, new or enlarging T2 lesions, 12-week CDA until EOS, and absence of annual brain volume decrease \>=0.4% from core baseline up to extension EOS. If at least one of the criteria was not fulfilled or the participant discontinued treatment prematurely, the participant was not considered to have achieved NEDA-4. Confirmed relapse: when patient's symptoms worsen by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging: 0 (normal)-10 (death due to MS). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in core study for each outcome measure and each participant individually.

Time frame:
From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Four Components (NEDA-4) at Extension End of Study
Percentage of ParticipantsPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Four Components (NEDA-4) at Extension End of Study5.22.3
PrimaryPercent Change From Baseline in Brain Volume (PCBV) Measured by Magnetic Resonance Imaging (MRI)

Percent change from baseline in brain volume (PCBV) measured by MRI were reported. Normalized Brain Volume at core baseline was measured in cubic centimeter (cm\^3). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.

Time frame:
From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
Reported as:
Mean · Percent Change
Percent Change From Baseline in Brain Volume (PCBV) Measured by Magnetic Resonance Imaging (MRI)
Percent ChangePonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Percent Change From Baseline in Brain Volume (PCBV) Measured by Magnetic Resonance Imaging (MRI)-2.52 ± 2.179-2.72 ± 2.024
PrimaryCumulative Number of Combined Unique Active Lesions (CUAL) Measured by MRI

CUALs was calculated as sum of new T1 Gadolinium-enhanced (Gd+) lesions and new or enlarging T2 lesions (without double-counting of lesions) from baseline up to extension EOS based on the Magnetic resonance imaging (MRI). Average number of lesions per patient-year were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.

Time frame:
From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Reported as:
Mean · CUAL per patient-year
Cumulative Number of Combined Unique Active Lesions (CUAL) Measured by MRI
CUAL per patient-yearPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Cumulative Number of Combined Unique Active Lesions (CUAL) Measured by MRI1.352 (1.153 to 1.586)1.954 (1.667 to 2.291)
PrimaryNumber of Gadolinium-enhancing (Gd+) T1 Lesions Measured by MRI

Number of Gd+ T1 lesions measured by MRI were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. For this outcome measure, results presented here are for the Extension end-of-treatment visit.

Time frame:
From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
Reported as:
Mean · Gd+ T1 lesions
Number of Gadolinium-enhancing (Gd+) T1 Lesions Measured by MRI
Gd+ T1 lesionsPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Number of Gadolinium-enhancing (Gd+) T1 Lesions Measured by MRI0.211 (0.131 to 0.341)0.395 (0.250 to 0.622)
PrimaryCumulative Number of New or Enlarging T2 Lesions Measured by MRI

Cumulative number of new or enlarging T2 lesions measured by MRI were reported. Average number of lesions per year were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.

Time frame:
From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Reported as:
Mean · Lesions per year
Cumulative Number of New or Enlarging T2 Lesions Measured by MRI
Lesions per yearPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Cumulative Number of New or Enlarging T2 Lesions Measured by MRI1.352 (1.152 to 1.586)1.951 (1.664 to 2.287)
PrimaryChange From Baseline in Volume of MRI Lesions (T2 Lesions and T1 Hypointense Lesions)

Change from baseline in volume of MRI lesions (T2 lesions, T1 hypointense lesions) were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.

Time frame:
From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
Reported as:
Mean · cubic millimeters (mm^3)
Change From Baseline in Volume of MRI Lesions (T2 Lesions and T1 Hypointense Lesions)
cubic millimeters (mm^3)Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
T2 Lesions-435.7 ± 2822.7191.5 ± 3647.08
T1 Hypointense Lesions165.6 ± 1427.30309.4 ± 1712.36
PrimaryNumber of Participants With Absence of MRI Lesions (Gd+ T1 Lesions, New or Enlarging T2 Lesions)

Number of participants with absence of MRI lesions (Gd+ T1 lesions, new or enlarging T2 lesions) were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.

Time frame:
From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
Reported as:
Count of participants · Participants
Number of Participants With Absence of MRI Lesions (Gd+ T1 Lesions, New or Enlarging T2 Lesions)
ParticipantsPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Gd+ T1 lesions293236
T2 lesions152101
PrimaryPercentage of Gd+ Lesions at Baseline Evolving to Persistent Black Holes (PBHs)

Percentage of Gd+ lesions at baseline evolving to PBHs were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.

Time frame:
From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
Reported as:
Number · Percentage of lesions
Percentage of Gd+ Lesions at Baseline Evolving to Persistent Black Holes (PBHs)
Percentage of lesionsPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Percentage of Gd+ Lesions at Baseline Evolving to Persistent Black Holes (PBHs)22.325.1
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs were reported. An AE is any untoward medical event that occurs in a participants being administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs occurring from start of treatment up to treatment end date + 15 days.

Time frame:
From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)411410
PrimaryNumber of Participants With Treatment-emergent New Morphological Electrocardiogram (ECG) Abnormalities

Number of participants with treatment-emergent new morphological ECG abnormalities were reported. Treatment-emergent new morphological ECG abnormalities are defined as those ECG abnormalities occurring from start of treatment up to treatment end date + 15 days.

Time frame:
From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent New Morphological Electrocardiogram (ECG) Abnormalities
ParticipantsPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Number of Participants With Treatment-emergent New Morphological Electrocardiogram (ECG) Abnormalities153140
PrimaryActual Values of 12-lead ECG Measurements up to End of Study Treatment: Heart Rate

Actual values of 12-lead ECG measurements up to end of study treatment: heart rate were reported. In this outcome measure, results were presented for extension end of treatment visit.

Time frame:
From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Reported as:
Mean · Beats per minute (bpm)
Actual Values of 12-lead ECG Measurements up to End of Study Treatment: Heart Rate
Beats per minute (bpm)Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Actual Values of 12-lead ECG Measurements up to End of Study Treatment: Heart Rate67.4 ± 9.6467.6 ± 9.33
PrimaryActual Values of 12-lead ECG Measurements up to End of Study Treatment: PR, QRS, QT, QTcB, QTcF

Actual values of 12-lead ECG measurements up to end of study treatment: PR, QRS, QT, QTcB, QTcF were reported. In this outcome measure, results were presented for extension end of treatment visit.

Time frame:
From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Reported as:
Mean · millisecond (ms)
Actual Values of 12-lead ECG Measurements up to End of Study Treatment: PR, QRS, QT, QTcB, QTcF
millisecond (ms)Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
PR Interval150.0 ± 20.41153.3 ± 20.27
QRS Duration92.1 ± 9.2293.3 ± 10.63
QT Interval392.5 ± 27.26391.0 ± 25.67
QTcB Interval414.8 ± 19.20413.8 ± 19.66
QTcF Interval406.9 ± 17.78405.7 ± 17.78
PrimaryChange in Heart Rate (HR) From Baseline up to End of Study Treatment

Change in heart rate (HR) from baseline up to end of study treatment were reported.

Time frame:
From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Reported as:
Mean · beats per minute (bpm)
Change in Heart Rate (HR) From Baseline up to End of Study Treatment
beats per minute (bpm)Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Change in Heart Rate (HR) From Baseline up to End of Study Treatment-1.7 ± 10.00-1.5 ± 9.17
PrimaryChange in PR, QRS, QT, QTcB, QTcF From Baseline up to End of Study Treatment

Change in PR, QRS, QT, QTcB, QTcF from baseline up to end of study treatment were reported.

Time frame:
From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Reported as:
Mean · millisecond (ms)
Change in PR, QRS, QT, QTcB, QTcF From Baseline up to End of Study Treatment
millisecond (ms)Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
PR Interval0.5 ± 14.092.0 ± 14.37
QRS Duration-0.4 ± 6.792.9 ± 6.88
QT Interval7.8 ± 25.688.9 ± 21.66
QTcB Interval2.9 ± 16.755.2 ± 17.07
QTcF Interval4.6 ± 15.286.5 ± 14.18
PrimaryAbsolute Values in Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) Values

Absolute values in FEV1 and FVC values were reported. FEV1: the maximal volume of air exhaled from the lungs in 1 second of a forced expiration from a position of full inspiration as measured by spirometer. FVC: the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. Results are presented for extension end of treatment visit.

Time frame:
From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Reported as:
Mean · Liters (L)
Absolute Values in Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) Values
Liters (L)Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
FEV13.01 ± 0.7683.08 ± 0.797
FVC-3.96 ± 0.9654.04 ± 1.031
PrimaryPercent Change in (FEV1) and Forced Vital Capacity (FVC) From Baseline (%)

Percent change in FEV1 and FVC from baseline (%) were reported. FEV1: the maximal volume of air exhaled from the lungs in 1 second of a forced expiration from a position of full inspiration as measured by spirometer. FVC: the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. In this outcome measure, results were presented for extension end of treatment visit.

Time frame:
From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Reported as:
Mean · Percent change
Percent Change in (FEV1) and Forced Vital Capacity (FVC) From Baseline (%)
Percent changePonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
FEV1-7.96 ± 13.356-6.75 ± 12.323
FVC-5.09 ± 11.793-3.93 ± 12.141
PrimaryNumber of Participants With Treatment-emergent Serious Adverse Events (SAEs)

Number of participants with treatment-emergent SAEs were reported. A SAE was defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or was an important medical event. Treatment-emergent SAEs are defined as SAEs occurring from start of treatment up to treatment end date + 15 days.

Time frame:
From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)
ParticipantsPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)56 (0.442 to —)57 (0.380 to —)
PrimaryNumber of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)

Number of participants with treatment-emergent AESIs were reported. AESIs included bradyarrhythmia occurred post-first dose, macular edema, bronchoconstriction, severe liver injury, serious opportunistic infections including progressive multifocal leukoencephalopathy (PML), skin cancer, non-skin malignancy, convulsions, unexpected neurological or psychiatric symptoms/signs (posterior reversible encephalopathy syndrome \[PRES\], acute disseminated encephalomyelitis \[ADEM\], and atypical MS relapses). Treatment-emergent AESIs are defined as AESIs occurring from start of treatment up to treatment end date + 15 days.

Time frame:
From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)
ParticipantsPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Bradyarrhythmia occurring post-first dose1113
Severe liver injury55
Bronchoconstriction3125
Macular edema46
Serious opportunistic infections including PML21
Skin cancer43
Non-skin malignancy43
Unexpected neurological or psychiatric symptoms / signs (PRES, ADEM, atypical MS relapses)12
Convulsions23
PrimaryNumber of Participants With AE Leading to Premature Discontinuation of Study Treatment

Number of participants with AE leading to premature discontinuation of study treatment were reported. An AE is any untoward medical event that occurs in a participant being administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs occurring from start of treatment up to treatment end date + 15 days.

Time frame:
From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Reported as:
Count of participants · Participants
Number of Participants With AE Leading to Premature Discontinuation of Study Treatment
ParticipantsPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Number of Participants With AE Leading to Premature Discontinuation of Study Treatment3441
PrimaryNumber of Participants With Treatment-emergent Decrease From Baseline >20% and >30% in FEV1 or FVC

Number of participants with treatment-emergent decrease from baseline \>20% and \>30% in FEV1 or FVC were reported. Treatment-emergent is defined as events occurring from start of treatment up to treatment end date + 15 days (that is, findings not present at any assessment prior to first treatment in the extension study).

Time frame:
From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Decrease From Baseline >20% and >30% in FEV1 or FVC
ParticipantsPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
FEV1: >20 %8082
FEV1: >30 %1821
FVC: >20 %5460
FVC: >30 %1915
PrimaryNumber of Participants With Treatment-emergent Decrease of >20% Points in Percent Predicted FEV1 and FVC From Baseline

Number of participants with treatment-emergent decrease of \>20% points in percent predicted FEV1 and FVC from baseline were reported. Treatment-emergent is defined as events occurring from start of treatment up to treatment end date + 15 days (that is, findings not present at any assessment prior to first treatment in the extension study).

Time frame:
From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Decrease of >20% Points in Percent Predicted FEV1 and FVC From Baseline
ParticipantsPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
FEV1: >20 %7068
FVC: >20 %5957
PrimaryNumber of Participants With a Decrease of >=200 mL or >=12% in FEV1 or FVC From Baseline to EOT

Number of participants with a decrease of \>=200 mL or \>=12% in FEV1 or FVC from baseline to EOT were planned to be reported. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. This endpoint is not relevant as a substantial proportion of patients continued onto post-treatment disease-modifying therapy (DMT), hence it cannot provide an assessment of reversibility.

Time frame:
From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months

No measurements were reported for this outcome.

PrimaryChange in FEV1 and FVC (% Predicted) From Baseline to End of Treatment (EOT)

Change in FEV1 and FVC (% predicted) from baseline to EOT were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.

Time frame:
From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Reported as:
Mean · Percentage predicted change
Change in FEV1 and FVC (% Predicted) From Baseline to End of Treatment (EOT)
Percentage predicted changePonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
FEV1-7.14 ± 13.315-5.43 ± 11.839
FVC-4.70 ± 13.129-3.19 ± 13.081
PrimaryChange in FEV1 and FVC (% Predicted) From Baseline to End of Study (EOS)

Change in FEV1 and FVC (% predicted) from baseline to EOS were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.

Time frame:
From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months
Reported as:
Mean · Percentage predicted change
Change in FEV1 and FVC (% Predicted) From Baseline to End of Study (EOS)
Percentage predicted changePonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
FEV1-5.95 ± 12.854-4.08 ± 14.365
FVC-4.48 ± 13.727-1.98 ± 15.747
PrimaryAbsolute Change in Lung Diffusion Capacity as Assessed by Diffusing Capacity for the Lungs Measured Using Carbon Monoxide (DL[CO]) From Baseline

Absolute change in lung diffusion capacity as assessed by DL\[CO\] from baseline were reported. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.

Time frame:
From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months
Reported as:
Mean · Millimoles/minute/kilopascal
Absolute Change in Lung Diffusion Capacity as Assessed by Diffusing Capacity for the Lungs Measured Using Carbon Monoxide (DL[CO]) From Baseline
Millimoles/minute/kilopascalPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Absolute Change in Lung Diffusion Capacity as Assessed by Diffusing Capacity for the Lungs Measured Using Carbon Monoxide (DL[CO]) From Baseline0.7 ± 3.440.1 ± 4.17
PrimaryChange in DL[CO] (% Predicted) From Baseline to EOT

Change in DL\[CO\] (% predicted) from baseline to EOT were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.

Time frame:
From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Reported as:
Mean · Percentage predicted DL[CO]
Change in DL[CO] (% Predicted) From Baseline to EOT
Percentage predicted DL[CO]Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Change in DL[CO] (% Predicted) From Baseline to EOT5.7 ± 32.20-9.4 ± 7.82
PrimaryChange in DL[CO] (% Predicted) From Baseline to EOS

Change in DL\[CO\] (% predicted) from baseline to EOS were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.

Time frame:
From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months
Reported as:
Mean · Percentage predicted DL[CO]
Change in DL[CO] (% Predicted) From Baseline to EOS
Percentage predicted DL[CO]Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Change in DL[CO] (% Predicted) From Baseline to EOS9.3 ± 39.382.2 ± 49.50
Other pre-specifiedActual Values of 12-lead ECG Measurements on Day of First Re-initiation (Day 1) of Study Drug: Heart Rate

Actual values of 12-lead ECG measurements on day of first Re-initiation (Day 1) of study drug: heart rate were reported.

Time frame:
Extension analysis period: Predose, 1, 2, 3, 4 hours post dose on Day 1 of re-initiation (re-initiation could occur on any day during the treatment period when drug was interrupted for at least 3 consecutive days [up to 71.8 months])
Reported as:
Mean · beats per minute (bpm)
Actual Values of 12-lead ECG Measurements on Day of First Re-initiation (Day 1) of Study Drug: Heart Rate
beats per minute (bpm)Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Predose68.1 ± 8.7371.0 ± 9.21
1 hour Post-dose66.5 ± 10.5369.0 ± 10.13
2 hours Post-dose64.3 ± 9.9165.1 ± 8.68
3 hours Post-dose64.6 ± 9.3367.8 ± 10.71
4 hours Post-dose66.0 ± 9.7367.6 ± 10.01
Other pre-specifiedActual Values of 12-lead ECG Measurements on Day of First Re-initiation (Day 1) of Study Drug: PR, QRS, QT, QTcB, QTcF

Actual values of 12-lead ECG measurements on day of first Re-initiation (Day 1) of study drug: PR, QRS, QT, QTcB, QTcF were reported.

Time frame:
Extension analysis period: Predose, 1, 2, 3, 4 hours post dose on Day 1 of re-initiation (re-initiation could occur on any day during the treatment period when drug was interrupted for at least 3 consecutive days [up to 71.8 months])
Reported as:
Mean · millisecond (ms)
Actual Values of 12-lead ECG Measurements on Day of First Re-initiation (Day 1) of Study Drug: PR, QRS, QT, QTcB, QTcF
millisecond (ms)Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
PR Interval: Predose152.8 ± 17.66149.8 ± 19.13
PR Interval: 1 hour Post-dose150.5 ± 17.25152.6 ± 22.66
PR Interval: 2 hours Post-dose150.1 ± 16.60153.6 ± 23.51
PR Interval: 3 hours Post-dose152.3 ± 17.73154.5 ± 21.91
PR Interval: 4 hours Post-dose150.7 ± 17.82151.8 ± 19.68
QRS Duration: Predose94.6 ± 11.0691.5 ± 7.03
QRS Duration: 1 hour Post-dose95.2 ± 11.4293.2 ± 8.72
QRS Duration: 2 hours Post-dose93.9 ± 11.7192.7 ± 7.57
QRS Duration: 3 hours Post-dose94.5 ± 11.6094.5 ± 7.80
QRS Duration: 4 hours Post-dose94.7 ± 10.4892.5 ± 7.35
QT Interval: Predose391.5 ± 24.80378.8 ± 23.61
QT Interval: 1 hour Post-dose396.7 ± 28.76380.9 ± 21.78
QT Interval: 2 hours Post-dose402.0 ± 29.00386.0 ± 19.62
QT Interval: 3 hours Post-dose400.2 ± 27.78386.9 ± 21.38
QT Interval: 4 hours Post-dose400.0 ± 27.49383.9 ± 23.14
QTcB Interval: Predose416.2 ± 19.05411.4 ± 20.85
QTcB Interval: 1 hour Post-dose416.0 ± 24.11407.6 ± 22.96
QTcB Interval: 2 hours Post-dose414.8 ± 22.83401.7 ± 20.88
QTcB Interval: 3 hours Post-dose414.2 ± 23.30410.1 ± 22.33
QTcB Interval: 4 hours Post-dose418.0 ± 20.30406.6 ± 22.33
QTcF Interval: Predose407.4 ± 17.09400.0 ± 18.69
QTcF Interval: 1 hour Post-dose409.2 ± 20.58398.1 ± 18.22
QTcF Interval: 2 hours Post-dose410.1 ± 20.41396.2 ± 16.61
QTcF Interval: 3 hours Post-dose409.0 ± 20.97402.0 ± 16.82
QTcF Interval: 4 hours Post-dose411.5 ± 18.36398.5 ± 18.27

Adverse events

Collected over Serious and Other AEs:From treatment start in extension study to EOT+15 days in extension study. Actual time varied till 71.8 months+15 days; All-cause mortality:From extension study baseline to EOS in extension study. Actual time varied till 73.2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ponesimod 20 mg (Core and Extension Study)1/439 (0.2%)56/439 (12.8%)339/439 (77.2%)
Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)0/438 (0%)57/438 (13%)328/438 (74.9%)
Most frequent serious events
Showing 10 of 131
Most frequent serious events
EventPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
AppendicitisInfections and infestations3/4393/438
Acute Myocardial InfarctionCardiac disorders0/4392/438
Umbilical HerniaGastrointestinal disorders0/4392/438
CholelithiasisHepatobiliary disorders0/4392/438
Covid-19 PneumoniaInfections and infestations1/4392/438
PneumoniaInfections and infestations0/4392/438
Upper Limb FractureInjury, poisoning and procedural complications0/4392/438
Spinal PainMusculoskeletal and connective tissue disorders0/4392/438
Multiple Sclerosis RelapseNervous system disorders1/4392/438
Complicated AppendicitisInfections and infestations2/4390/438
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPonesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)
Covid-19Infections and infestations115/439108/438
Alanine Aminotransferase IncreasedInvestigations73/43998/438
NasopharyngitisInfections and infestations82/43974/438
LymphopeniaBlood and lymphatic system disorders66/43964/438
HeadacheNervous system disorders57/43964/438
Upper Respiratory Tract InfectionInfections and infestations47/43951/438
Back PainMusculoskeletal and connective tissue disorders45/43930/438
HypertensionVascular disorders37/43944/438
ArthralgiaMusculoskeletal and connective tissue disorders31/43938/438
Urinary Tract InfectionInfections and infestations36/43933/438

Baseline characteristics

The extension set included all participants who signed an informed consent to enter the extension study and who received at least one dose of ponesimod study medication in the extension study.

Age, Categorical
Age, Categorical(Participants)Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)Total
<=18 years000
Between 18 and 65 years439438877
>=65 years000
Age, Continuous
Age, Continuous(years)Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)Total
Mean36.5 ± 8.7537.2 ± 8.7536.8 ± 8.75
Sex: Female, Male
Sex: Female, Male(Participants)Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)Total
Female286290576
Male153148301
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)Total
Hispanic or Latino221739
Not Hispanic or Latino409411820
Unknown or Not Reported81018
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ponesimod 20 mg (Core and Extension Study)Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American224
White429430859
More than one race000
Unknown or Not Reported8614
08

Study locations

148 sites
  • The Research Center of Southern California, LLC
    Carlsbad, California 92011, United States
  • The Neurology Group
    Pomona, California 91767, United States
  • Mountain View Clinical Research
    Denver, Colorado 80209, United States
  • Neurology Associates of Ormond Beach
    Ormond Beach, Florida 32174, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Josephson Wallack Munshower Neurology, PC
    Indianapolis, Indiana 46256, United States
  • Raleigh Neurology Associates
    Raleigh, North Carolina 27607, United States
  • Ohio Health
    Columbus, Ohio 43214, United States
  • Advanced Neurosciences Institute
    Franklin, Tennessee 37064, United States
  • Grodno University Hospital
    Grodno, 230017, Belarus
  • Minsk City Clinical Hospital 5
    Minsk, 220026, Belarus
  • Republican Scientific Clinical Centre
    Minsk, 220114, Belarus
  • Vitebsk Regional Diagnostic Center
    Vitebsk, 210023, Belarus
  • Vitebsk Regional Clinical Hospital
    Vitebsk, 210037, Belarus
  • University Clinicl Center Sarajevo
    Sarajevo, 71000, Bosnia and Herzegovina
  • UMHAT Sveti Georgi
    Plovdiv, 4002, Bulgaria
  • Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum
    Sofia, 1113, Bulgaria
  • Multiprofile Hospital For Active Treatment National Cardiology Hospital, Ead
    Sofia, 1309, Bulgaria
  • Acibadem City Clinic Tokuda Hospital
    Sofia, 1407, Bulgaria
  • St Ivan Rilski University Multiprofile Hospital For Active Treatment
    Sofia, 1431, Bulgaria
  • University Multiprofile Hospital for Active Treatment Alexandrovska EAD
    Sofia, 1431, Bulgaria
  • Military Medical Academy Multiprofile Hospital for Active Treatment Sofia
    Sofia, 1606, Bulgaria
  • University of Alberta
    Edmonton, Alberta T6G 1Z1, Canada
  • Royal Jubilee Hospital
    Victoria, British Columbia V8R 1J8, Canada
  • Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Recherche Sepmus Inc.
    Greenfield Park, Quebec J4V 2J2, Canada
  • Ch Osijek
    Osijek, 31000, Croatia
  • University Hospital Center Zagreb
    Zagreb, 10000, Croatia
  • Fakultní nemocnici Brno
    Brno, 65691, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Králové, 500 05, Czechia
  • Nemocnice Jihlava
    Jihlava, 586 33, Czechia
  • Fakultni Nemocnice Ostrava
    Ostrava-Poruba, 708 52, Czechia
  • Pardubicka krajska nemocnice a s
    Pardubice, 532 03, Czechia
  • Vseobecna Fakultní Nemocnice
    Praha 2, 128 08, Czechia
  • FN Motol
    Praha 5, 150 06, Czechia
  • Krajska zdravotni, a.s. - Nemocnice Teplice, o.z.
    Teplice, 415 29, Czechia
  • Suomen Terveystalo Tampere
    Tampere, 33100, Finland
  • Mehilainen NEO
    Turku, 20520, Finland
  • Hopital Pellegrin CHU Bordeaux
    Bordeaux cedex, 33076, France
  • CHU Clermont-Ferrand - Hopital Gabriel Montpied
    Clermont Ferrand Cedex 1, 63003, France
  • Hopital Nord Laennec CHU NANTES
    Nantes Cedex 1, 44093, France
  • Hopital PASTEUR
    Nice, 6000, France
  • Nouvel Hopital Civil
    Strasbourg CEDEX, 67091, France
  • LTD 'Aversi Clinic'
    T'bilisi, 0160, Georgia
  • P. Sarajishvili Institute of Neurology
    Tbilisi, 112, Georgia
  • Pineo Medical Ecosystem Ltd
    Tbilisi, 114, Georgia
  • S.Khechinashvili University Hospital
    Tbilisi, 179, Georgia
  • Curatio, Jsc
    Tbilisi, 186, Georgia
  • Universitätsklinikum Carl-Gustav-Carus Dresden
    Dresden, 1307, Germany
  • Helios Klinikum Erfurt
    Erfurt, 99089, Germany
  • Panakeia - Arzneimittelforschung GmbH
    Leipzig, 04275, Germany
  • Universitatsmedizin der Johannes Gutenberg Universitat Mainz
    Mainz, 55131, Germany
  • 401 Military Hospital
    Athens, 115 25, Greece
  • Naval Hospital of Athens
    Athens, 11521, Greece
  • Medical Center of Athens
    Marousi, 15125, Greece
  • Uzsoki Utcai Korhaz
    Budapest, 1145, Hungary
  • Jahn Ferenc Del-pesti Korhaz es Rendelointezet
    Budapest, 1204, Hungary
  • Valeomed EGÉSZSÉGÜGYI KÖZPONT
    Esztergom, 2500, Hungary
  • Petz Aladar Megyei Oktato Korhaz
    Győr, 9023, Hungary
  • Kistarcsai Flor Ferenc Korhaz
    Kistarcsa, 2143, Hungary
  • Barzilai Medical Center
    Ashkelon, 7830604, Israel
  • Rambam Medical Center
    Haifa, 3109601, Israel
  • Hadassah Medical Center
    Jerusalem, 9112001, Israel
  • Ziv Medical Center
    Safed, 1304300, Israel
  • Ospedale San Salvatore
    L' Aquila, 67100, Italy
  • Azienda Ospedaliera Sant Andrea
    Roma, 189, Italy
  • Pauls Stradins Clinical University Hospital
    Riga, 1002, Latvia
  • Latvias Juras medicinas centrs Ltd
    Riga, 1015, Latvia
  • Rīgas Austrumu klīniskā universitātes slimnīca
    Riga, LV-1038, Latvia
  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
    Kaunas, LT50161, Lithuania
  • VsI Respublikine Siauliu ligonine, V.
    Šiauliai, 76231, Lithuania
  • Unidad de Investigacion En Salud
    Chihuahua, 31203, Mexico
  • CRI Centro Regiomontano de Investigacion SC
    Nuevo Leon, 64060, Mexico
  • Neurocentrum Bydgoszcz Sp Z O O
    Bydgoszcz, 85 796, Poland
  • Copernicus Podmiot Leczniczy Sp. z o.o
    Gdansk, 80-803, Poland
  • Neuro Centrum Centrum Terapii SM
    Katowice, 40 571, Poland
  • NEURO MEDIC Janusz Zbrojkiewicz Poradnia Wielospecjalistyczna
    Katowice, 40 686, Poland
  • Centrum Kompleksowej Rehabilitacji
    Konstancin Jeziorna, 05 510, Poland
  • Centrum Opieki Zdrowotnej Orkan Med
    Ksawerow, 95 054, Poland
  • Indywidualna Praktyka Lekarska Prof. Konrad Rejdak
    Lublin, 20-410, Poland
  • Szpital Kliniczny im Heliodora Swiecickiego Uniwersytetu Medycznego im Karola Marcinkowskiego w Po
    Poznan, 60 355, Poland
  • Clinical Research Center sp z o o MEDIC R s k
    Poznan, 61 731, Poland
  • NZOZ NEURO KARD Ilkowski i Partnerzy Sp Partnerska Lekarzy
    Poznan, 61 853, Poland
  • WroMedica I Bielicka A Strzalkowska s c
    Wroclaw, 51 685, Poland
  • Hospital de Braga
    Braga, 4710-243, Portugal
  • Hospitais da universidade de Coimbra
    Coimbra, 3000-075, Portugal
  • Hosp. Cuf Descobertas
    Lisboa, 1998-018, Portugal
  • H. Santo António - Centro Hospitalar do Porto
    Porto, 4099-001, Portugal
  • Spitalul Universitar de Urgenta Militar Central 'Dr. Carol Davila'
    Bucuresti, 10825, Romania
  • Institutul Clinic Fundeni
    Bucuresti, 22328, Romania
  • Spitalul Universitar de Urgenta Bucuresti
    Bucuresti, 50098, Romania
  • Spitalul Clinic Judetean de Urgenta Pius Brinzeu
    Timisoara, 300723, Romania
  • Barnaul Territorial Clinical Hospital
    Barnaul, 656024, Russian Federation
  • St. Joseph Belgorod Regional Hospital
    Belgorod, 308007, Russian Federation
  • Bryansk Regional Hospital #1
    Bryansk, 241033, Russian Federation
  • Sverdlovsk Region Clinical Hospital #1
    Ekaterinburg, 620102, Russian Federation
  • Research Medical Center Your Health
    Kazan, 420097, Russian Federation
  • Federal State Budgetary Institution
    Krasnoyarsk, 660037, Russian Federation
  • State Budgetary Healthcare Institution Kursk Region Kursk Regional Clinical Hospital
    Kursk, 305007, Russian Federation
  • Clinical City Hospital #1
    Moscow, 117049, Russian Federation

Showing the first 100 of 148 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Jan 2024, 78 months.

Results were first posted in Feb 2025, 1 year 1 month after primary completion.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 78 months is above that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2017
First posted
Jul 27, 2017
StartActual
Jul 5, 2017
Primary completionActual
Jan 16, 2024
CompletionActual
Jan 16, 2024
Results first posted
Feb 21, 2025
Last update
Jun 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03232073
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Jul 27, 2017
Start date
Jul 5, 2017
Primary completion
Jan 16, 2024
Completion
Jan 16, 2024
Results posted
Feb 21, 2025
Last update
Jun 22, 2025

Study contacts

Tatiana Sidorenko, MD, PhD
study director · Actelion

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponesimod

Start the discussion